Exemestane is a third-generation aromatase inhibitor originally developed by Pharmacia & Upjoin (now a subsidiary of Pfizer). It was first approved in the UK in April 1999 and has been marketed in several countries for clinical use in the treatment of advanced breast cancer in postmenopausal women. Exemestane tablets are an effective and selective treatment for postmenopausal hormone-dependent breast cancer. Exemestane tablets, as third-generation aromatase inhibitors, are with strong selectivity and long-lasting effects. They can also control breast cancer growth by inhibiting aromatase and blocking estrogen production.

According to CRI’s market research, Pharmacia & Upjoin’s exemestane was not introduced into the Chinese market until 2008, when several generic drugs from local Chinese companies were already available in the Chinese market, of which the exemestane tablets from Qilu Pharmaceutical was already marketed in China in 2002. Pharmacia &Upjoin’s exemestane (trade name AROMASIN^®) is extremely competitive in the Chinese market, accounting for more than 90% of China’s exemestane market in 2020 in terms of sales value. Despite the impact of the COVID-19 outbreak on the Chinese healthcare industry in early 2020, the sales value of exemestane in the Chinese market continued to grow in 2020, reaching approximately CNY400 million (USD61.6 million), with a CAGR of 9.2% from 2016 to 2020.

Breast cancer has replaced lung cancer as the number one cancer worldwide due to the rapid growth in the number of new cases in 2020. The increasing breast cancer cases are fundamentally caused by the altering risk factors for breast cancer, such as changing lifestyles and notions of marriage and childbearing due to economic growth, namely a general rise in the age of women having children, a decrease in the average number of births, overweight, obesity and lack of exercise, all contributing to the increase in the incidence of breast cancer. CRI expects that from 2021 to 2025, new cases of breast cancer in China will continue to grow, resulting in increases in both sales volume and value of exemestane in the Chinese market.

Topics Covered:

• Impact of COVID-19 on China’s Exemestane Market
• Development Environment of Exemestane in China
• Sales Volume of Exemestane in China
• Sales Volume and Value of Exemestane in China by Region
• Major Exemestane Manufacturers in China and Their Market Shares
• Sales Price of Exemestane in China
• Prospects of China’s Exemestane Market, 2021-2025

The post Research Report on China’s Exemestane Market, 2021-2025 first appeared on CRI Report.

Unlike other tumors, breast cancer can also be treated by endocrine therapy beside conventional treatments such as surgery, radiotherapy and chemotherapy. Endocrine therapy is applied to the whole treatment process of breast cancer patients from early adjuvant treatment to postoperative adjuvant treatment and recurrence salvage in clinical practice because it boasts good curative effect and can greatly reduce the risk of cancer coming back. Endocrine therapy for breast cancer is mainly achieved by oral medications.

Drugs for breast cancer endocrine therapy are divided into three categories, estrogen receptor modulators, aromatase inhibitors and estrogen receptor down-regulators. Anastrozole belongs to the second category and is indicated for the treatment of advanced breast cancer in postmenopausal women. Patients who are estrogen receptor negative but tamoxifen positive can take it. Anastrozole is also indicated for the adjuvant treatment of estrogen receptor-positive early-stage breast cancer in postmenopausal women.

Anastrozole was developed by AstraZeneca with Arimidex as its trade name. And it was first marketed in the United States in 1995, approved by the FDA of U.S. for the treatment of advanced breast cancer in postmenopausal women. 1999 saw the introduction of AstraZeneca’s anastrozole into China, where it was approved for use in the adjuvant treatment of estrogen receptor-positive early-stage breast cancer in postmenopausal women. In the following years, generic versions of anastrozole were launched by local Chinese companies. According to CRI’s market research, AstraZeneca still occupied more than 80% of China’s anastrozole market share in 2020 in terms of market value, thus having a huge competitive advantage.

According to CRI’s survey data, the sales value of anastrozole in China kept increasing year by year from 2016 to 2020, not much impacted by COVID-19. In 2020, the sales value of anastrozole in China was about CNY452 million, with a CAGR of 12.1% from 2016 to 2020.

CRI expects that with the rising incidence of breast cancer in China, anastrozole still has significant room for growth in the Chinese market. In addition, compared with other drugs of the same category, anastrozole has been clinically used earlier and is reimbursable under the medical insurance with little cost, and it has relatively fewer side effects as well. Some studies suggest that anastrozole may reduce the risk of invasive estrogen receptor-positive breast cancer and ductal carcinoma in situ in a high-risk postmenopausal breast population. New indications for anastrozole are also expected to be approved in China soon. According to CRI’s estimation, from 2021 to 2025, the sales volume and value of anastrozole in China will continue to grow.

Topics Covered:

• The Impact of COVID-19 on China’s Anastrozole Market
• Development Environment of Anastrozole in China
• Sales Volume of Anastrozole in China
• Sales Volume and Value of Anastrozole in China by Region
• Major Anastrozole Manufacturers in China and Their Market Share
• Sales Price of Anastrozole in China
• Prospects of China’s Anastrozole Market, 2021-2025

The post Research Report on China’s Anastrozole Market, 2021-2025 first appeared on CRI Report.